Sign Up to like & get
recommendations!
0
Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e19019
Abstract: e19019 Background: Bruton's tyrosine kinase inhibitors (BTKis) and the B-cell lymphoma 2 inhibitor (BCL2i) venetoclax have improved outcomes and achieved durable remission in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) in both first-line…
read more here.
Keywords:
double exposed;
efficacy;
cll sll;
efficacy outcomes ... See more keywords